WILMINGTON, Del. and ABBOTT PARK, Ill., March 30 /PRNewswire-FirstCall/ -- AstraZeneca and Abbott announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for the New Drug Application (NDA) for CERTRIAD(TM) (rosuvastatin / fenofibric acid delayed release) Capsules. The companies are currently evaluating the CRL, will continue discussions with the FDA to determine next steps with respect to the CERTRIAD NDA and will respond to the agency's request for additional information.
For more information about AstraZeneca in the US or the AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Abbott
